Galmed Pharmaceuticals (GLMD) Non-Current Deffered Revenue (2016 - 2017)
Galmed Pharmaceuticals (GLMD) recorded quarterly Non-Current Deffered Revenue of $270000.0 in Q1 2017, down 48.96% quarter-over-quarter from $529000.0 in Q4 2016.
Galmed Pharmaceuticals (GLMD) Non-Current Deffered Revenue (2016 - 2017) Analysis & Trends
Galmed Pharmaceuticals' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $270000.0 for Q1 2017.
- In Q1 2017, Non-Current Deffered Revenue changed N/A year-over-year to $270000.0; the TTM figure through Mar 2017 stood at $270000.0 (changed N/A YoY), while the FY2016 annual figure was $529000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $270000.0 for Q1 2017 at Galmed Pharmaceuticals, down from $529000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $852000.0 in Q3 2016 to a low of $270000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 270,000.00 |
| Dec 31, 2016 | 529,000.00 |
| Sep 30, 2016 | 852,000.00 |